In Vivo Transcriptional Activation Using CRISPR/Cas9 in Drosophila

Abstract

A number of approaches for Cas9-mediated transcriptional activation have recently been developed, allowing target genes to be overexpressed from their endogenous genomic loci. However, these approaches have thus far been limited to cell culture, and this technique has not been demonstrated in vivo in any animal. The technique involving the fewest separate components, and therefore the most amenable to in vivo applications, is the dCas9-VPR system, where a nuclease-dead Cas9 is fused to a highly active chimeric activator domain. In this study, we characterize the dCas9-VPR system in Drosophila cells and in vivo. We show that this system can be used in cell culture to upregulate a range of target genes, singly and in multiplex, and that a single guide RNA upstream of the transcription start site can activate high levels of target transcription. We observe marked heterogeneity in guide RNA efficacy for any given gene, and we confirm that transcription is inhibited by guide RNAs binding downstream of the transcription start site. To demonstrate one application of this technique in cells, we used dCas9-VPR to identify target genes for Twist and Snail, two highly conserved transcription factors that cooperate during Drosophila mesoderm development. In addition, we simultaneously activated both Twist and Snail to identify synergistic responses to this physiologically relevant combination. Finally, we show that dCas9-VPR can activate target genes and cause dominant phenotypes in vivo, providing the first demonstration of dCas9 activation in a multicellular animal. Transcriptional activation using dCas9-VPR thus offers a simple and broadly applicable technique for a variety of overexpression studies.

Cancer Drug Development Using Drosophila as an in vivo Tool: From Bedside to Bench and Back

“…With the advent of the clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) 9-based genome editing tool, researchers can now alter the genomes of a large variety of organisms, including Drosophila, with unprecedented ease, specificity, efficiency, and low cost [98][99][100]. The technology has the potential to permanently correct genetic…”

Drosophilaas a model to study obesity and metabolic disease

“…Particularly promising in this respect are in vivo CRISPR transcriptional activation (CRISPRa) and interference (CRISPRi) approaches (Ghosh et al, 2016;Lin et al, 2015a), which allow tightly regulated and reversible promoter activation and blocking, respectively.…”

Loss-of-function genetic tools for animal models: cross-species and cross-platform differences

“…Although these tools have only been tested to a limited extent, initial results are promising. For example, these tools have been used in D. melanogaster 114,115 , C. elegans 116 and zebrafish 116,117 for single-gene studies and also genome-wide in mammalian cell culture 118,119 .…”